T
Tarec Christoffer El-Galaly
Researcher at Aalborg University
Publications - 158
Citations - 2396
Tarec Christoffer El-Galaly is an academic researcher from Aalborg University. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 24, co-authored 121 publications receiving 1701 citations. Previous affiliations of Tarec Christoffer El-Galaly include Sahlgrenska University Hospital & Aarhus University Hospital.
Papers
More filters
Journal ArticleDOI
Routine Bone Marrow Biopsy Has Little or No Therapeutic Consequence for Positron Emission Tomography/Computed Tomography–Staged Treatment-Naive Patients With Hodgkin Lymphoma
Tarec Christoffer El-Galaly,Francesco d'Amore,Karen Juul Mylam,Peter de Nully Brown,Martin Bøgsted,Anne Bukh,Lena Specht,Annika Loft,Victor Vishwanath Iyer,Karin Hjorthaug,Anne Lerberg Nielsen,Ilse Christiansen,Charlotte Madsen,Hans-Erik Johnsen,Martin Hutchings +14 more
TL;DR: A consistent finding of this study was the absence of positive BMBs in PET/CT-assessed stage I to II disease, suggesting the omission of staging BMB would not have changed the risk assessment or treatment strategy in this cohort of 454 newly diagnosed patients with HL.
Journal ArticleDOI
Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes With Prognosis
Karen Dybkær,Martin Bøgsted,Steffen Falgreen,Julie Støve Bødker,Malene Krag Kjeldsen,Alexander Schmitz,Anders Ellern Bilgrau,Zijun Y. Xu-Monette,Ling Li,Kim Steve Bergkvist,Maria Bach Laursen,Maria Rodrigo-Domingo,Sara Correia Marques,Sophie Bech Rasmussen,Mette Nyegaard,Michael Gaihede,Michael Boe Møller,Richard J. Samworth,Rajen D. Shah,Preben Johansen,Tarec Christoffer El-Galaly,Ken H. Young,Hans Erik Johnsen +22 more
TL;DR: Among R-CHOP-treated patients, BAGS assignment was significantly associated with overall survival and progression-free survival within the germinal center B-cell-like subclass; the centrocyte subtype had a superior prognosis compared with the centROblast subtype.
Journal ArticleDOI
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.
Gita Thanarajasingam,Lori M. Minasian,Frédéric Baron,Franco Cavalli,R. Angelo de Claro,Amylou C. Dueck,Tarec Christoffer El-Galaly,Neil Everest,Jan Geissler,Christian Gisselbrecht,John G. Gribben,Mary M. Horowitz,S. Percy Ivy,Caron A. Jacobson,Armand Keating,Paul G. Kluetz,Aviva C Krauss,Yok-Lam Kwong,Richard F. Little,François Xavier Mahon,Matthew J. Matasar,Maria-Victoria Mateos,Kristen B. McCullough,Robert S. Miller,Mohamad Mohty,Philippe Moreau,Lindsay M. Morton,Sumimasa Nagai,Sumimasa Nagai,Simon Rule,Jeff A. Sloan,Pieter Sonneveld,Carrie A. Thompson,Kyriaki Tzogani,Flora E. van Leeuwen,Galina Velikova,Diego Villa,John R. Wingard,Sophie Wintrich,John F. Seymour,John F. Seymour,John F. Seymour,Thomas M. Habermann +42 more
TL;DR: The aim of this Commission is to improve toxicity assessment in clinical trials in haematological malignancies by critically examining the current process of adverse event assessment, highlighting the need to incorporate patient-reported outcomes, and evaluating toxicity in real-world patients.
Journal ArticleDOI
Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs
Tarec Christoffer El-Galaly,Karen Juul Mylam,Peter de Nully Brown,Lena Specht,Ilse Christiansen,Lars Munksgaard,Hans Erik Johnsen,Annika Loft,Anne Bukh,Victor Vishwanath Iyer,Anne Lerberg Nielsen,Martin Hutchings +11 more
TL;DR: With no proven survival benefit for patients with a pre-clinically diagnosed relapse, the high costs and low positive predictive value make positron emission tomography/computed tomography unsuitable for routine surveillance of patients with Hodgkin lymphoma.
Journal ArticleDOI
FDG-PET/CT in the management of lymphomas: current status and future directions.
Tarec Christoffer El-Galaly,Diego Villa,Lars C. Gormsen,Joachim Baech,Andrea Lo,Chan Yoon Cheah +5 more
TL;DR: FDG‐PET/CT plays major roles in the various phases of management of lymphoma and constitutes a step towards the pursuit of personalized treatment.